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Metabolic syndrome (MetS) is a well-recognized cluster of cardiovascular (CV) risk factors including obesity, hypertension,
dyslipidemia, and hyperglycaemia, closely associated with an increased risk of forthcoming cardiovascular disease and type 2
diabetesmellitus. Emerging evidence indicates that benign prostate hyperplasia (BPH) and its related lower urinary tract symptoms
(LUTS) represent other clinical conditions frequently observed in subjects with MetS. Several modifiable factors involved in MetS
determinism, such as inadequate diet, lack of physical exercise, and smoking and drinking behaviours are emerging as main
contributors to the development of BPH. The pathogenetic mechanisms underlying the connection between MetS and BPH have
not been completely clarified. MetS and its components, hypogonadism, and prostate inflammation probably play an important
role in inducing BPH/LUTS. Although historically considered as a “normal” consequence of the aging process, BPH/LUTS should
now be faced proactively, as a preventable disorder of the elderly. Type of diet and level of physical activity are now considered
important factors affecting prostate health in the aging male. However, whether physical exercise, weight loss, and modifications
of dietary habit can really alter the natural history of BPH/LUTS remains to be determined. Further research is advisable to better
clarify these points.
1. Introduction
Time is an absolute dimension which ranks events as past,
present, and future. Since biological aging is the accumulation
and stratification of time-associated changes in a person,
aging is an inevitable phenomenon, and, as such, it must
be accepted. Because rejuvenation is impossible, the health-
care intervention in aging should be focused on formatting
this biological process as an acceptable lifetime season and,
therefore, as healthy as possible. We strongly believe that
acting on modifiable factors—such as going to the primary
care doctor routinely, a healthy diet, or smoking cessation—
can reduce an individual’s absolute propensity to aging. In
contrast, chronic morbidities—such as cardiovascular dis-
eases (CVD), type 2 diabetesmellitus (T2DM), osteoarthritis,
and mental disabilities—are conditions that seniors often
face as they age and that impair their enjoyment of this
late lifetime season. Low-grade inflammation is supposed
to represent the common determinant underlying almost
all the aforementioned, age-related, and degenerative health
conditions [1]. In fact, almost 10 years ago, Time magazine,
on its cover, labeled inflammation as “The Secret Killer”
for human health (http://content.time.com/time/magazine/
article/0,9171,993419,00.html). However, inflammation per se
is a beneficial reaction of the body, and its innate immune
system, to an injurious stimulus, recognized 2000 years ago
in the pioneering work of Celsius.
The concept of metabolic syndrome (MetS) was intro-
duced almost 60 years ago, but only recently it was recog-
nized as a valid construct to cluster some common medi-
cal disorders—such as visceral obesity, glucose intolerance,
hypertension, and dyslipidemia—which increase the odds for
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CVD and T2DM [2]. Even in the case of MetS, chronic, low-
grade inflammation is considered, in concert with insulin
resistance, the milestone of the syndrome. In the male,
three other bothersome, age-related conditions were recently
proposed as new factors often associated with MetS [2–
4]. They are hypogonadism, erectile dysfunction (ED), and
benign prostate hyperplasia (BPH). These age-associated
medical conditions have a relatively high socioeconomic bur-
den and are generally not regarded as preventable ailments.
In contrast, we strongly believe that their impact on male
aging can be halted by lifestyle changes or at least buffered
by available medications. In this study we will overview
pathogenetic interconnections between BPH, inflammation,
MetS and hypogonadism, highlighting possible interventions
to prevent their negative effect onmen’s health. In fact, several
modifiable factors, such as inadequate diet, lack of physical
exercise, and smoking and drinking behaviors, are emerging
as main contributors to the development of MetS and its
related disorders, including BPH.
2. BPH/LUTS and Hypogonadism
Androgens play an essential role in the development and
growth of the entire male genital tract and in particular
of the prostate, stimulating differentiation and proliferation
of both the epithelial and the stromal compartments of
the gland. Androgens acts through activation of androgen
receptor (AR), which is expressed in both prostatic stromal
and epithelial cells.
2.1. Androgens and Prostate Differentiation. The differentiat-
ing and growth-promoting actions of androgens are exerted
starting in early embryonic life and still persist in adulthood
and senescence. In fetal life, the AR-induced differentiation
and branching morphogenesis was deeply explored by the
Cunha laboratory, which demonstrated the role of androgens
in mesenchyme cell-induced prostatic development [5, 6].
Cunha et al. [7, 8] found that androgens could stimu-
late prostatic epithelial development and growth interacting
with AR within the stromal tissue, under the influence of
specific growth factors. This concept was originally based
on tissue recombinant experiments, composed of wild-type
stromal cells and AR-deficient epithelium from the testicular
feminization mouse. During prostatic development, several
growth factors, termed andromedins (IGF-1, EGF, and sev-
eral FGF-related proteins), have been proposed to be the
paracrine mediators of these androgen-induced, stromal-
mediated, generation of prostatic epithelial buds, and subse-
quent ductal elongation and branchingmorphogenesis [9]. In
the adult prostate, AR expression drives basal epithelial cells
of the glands into differentiation to generate intermediate
cells and into terminal differentiated luminal cells [10]. As a
caveat of these prodifferentiating actions of androgens, recent
studies indicate that hypogonadism is associated with a more
aggressive phenotype of prostate cancer [11].
2.2. Androgens and Prostate Growth. Besides differentiation,
another biological action of androgens in the prostate is to
promote growth [12], which is essentially orchestrated in
three distinct waves. The first growth wave is completed at
birth, when the average weight of the prostate is about 1.5
grams. Prostatic development at this stage is a clear function
of androgen signaling and is dependent on the function of
the fetal testis. After a quiescent phase, at puberty—under
the influence of increasing testosterone—the second wave
starts: the prostate size reaches approximately 10 grams at
early puberty and almost double that around the age of twenty
[13].Thereafter, the size of the prostate remains constant until
midlate adulthood. At that time, in contrast to the pubertal
growth phase which involves the entire gland, often there
is a third selective growth phase, involving one of the three
anatomically distinct prostate zones, the periurethral one,
and which gives rise to BPH. BPH is a condition extremely
prevalent in male adulthood and senescence, affecting 42%
of men in the fifth decade to almost 90% in men older than
80 years [14]. BPH is essentially a histological diagnosis, char-
acterized by hyperproliferation of the stromal and, to a lesser
extent, of the epithelial compartment of the prostate, which
can be clinically manifested as benign prostate enlargement
(BPE), in almost half of the cases, or, less often, as benign
prostate obstruction (BPO). The latter two clinical entities
are characterized by progressive development of symptoms
(lower urinary tract symptoms, LUTS), that are derived from
prostate enlargement to the point where urination becomes
difficult (BPE) or impaired (BPO), due to mechanical pres-
sure on the bladder and urethra. Approximately 25% of men
in their 50s and 80% of men in their 70s have clinically
significant LUTS. However, not all men with BPH develop
LUTS. In addition, not all men with LUTS have BPH as the
underlying cause, because they are not disease-specific, being
often multifactorial.
Although an increased androgen signaling is clearly
implicated in the first two waves of prostate growth, its
role in the third phase, BPH, is a matter of debate. In
fact, a clear dose-response relationship between circulating
androgen levels and BPH has never been demonstrated [15,
16]. In addition, during male senescence, androgens tend
to decrease and not to increase [17]. Several recent studies
indicate that a low testosterone (T), more than a high T,
might have a detrimental effect on prostate biology. In fact,
LUTS can even be lessened by androgen supplementation in
hypogonadal men [18–25]. Recent data indicate that not only
low testosterone but also high estradiol can favor BPH/LUTS
progression. It is important to note that circulating T is
actively metabolized to estrogens and part of T hormonal
activity depends upon its binding to the estrogen receptors
(ERs), that are present in both the prostate and bladder
[26]. In addition, the enzyme P450 aromatase which converts
androgens to estrogens [27] is highly expressed not only in
fat tissue but also in the urogenital tract [28]. Evidence of an
increased estrogen/androgen ratio was originally provided by
Marmorston et al. almost half a century ago [29] reporting
that the estrogen/androgen ratio in 24-hour urinary collec-
tions was elevated in men with BPH, as compared to normal
controls. Several studies have observed a correlation between
plasma 17𝛽estradiol (17𝛽E
2
) levels and prostate volume or
other features of BPH [30–32], while others have not [33].
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Figure 1: Association between insulin levels and prostate total or transitional zone volume. Association between insulin levels and prostate
total (a) or transitional zone (b) volume. Insulin levels are reported as quartiles. All data are adjusted for age and total testosterone. Data are
derived from a series of subjects seeking medical care for coupler infertility at our unit. The number of subjects with available parameters is
reported in the inset. Note that the statistical analyses have been performed using insulin levels as a continuous variable, even if grouped in
quartiles for graphical purposes.
In two longitudinal, population-based cohort studies it was
recently shown that a higher baseline 17𝛽E
2
was associated
with a worse forthcoming maximal flow rate and urinary
symptoms [34, 35].
3. BPH/LUTS and Metabolic Syndrome
The historical view that BPH-related LUTS are merely gener-
ated by the compression of the urethra through the volumet-
ric increased transitional prostate has been heavily challenged
in the last few years [36]. In fact, nowadays, BPH/LUTS are
not only viewed as a mere hydraulic problem, to be solved
by a surgical intervention, but as a metabolic problem, to
be solved with a multidisciplinary approach, which includes
also the endocrinologist. Several recent studies have provided
convincing evidence of a possible role of MetS, and/or its
individual components, in the development of BPH, prostate
growth, and worsening of LUTS [36].
3.1. Hyperinsulinemia, Glucose Intolerance/T2DM, and BPH.
Possible links between BPH and T2DM were noted, in a
retrospective study, as far back as 1966 [37]. Since that time,
hyperinsulinaemia/glucose intolerance (the key component
of MetS) and even T2DM have been considered as potential
risk factors for BPH/LUTS based on several studies [38, 39].
In a population-based cohort of African-Americanmen aged
40–79 years, BPH patients reporting a diabetes history have
a 2-fold increase in the risk of moderate-severe LUTS [40].
In diabetic individuals, a similar odds ratio for having LUTS
was reported in the second Nord-Trondelag Health Study
[41]. In a stepwise regression analysis, Nandeesha et al. [42]
found that insulin levels were an independent predictor of
prostate volume in symptomatic BPH patients aged over
sixty. Interestingly, a similar conclusion was drawn by us
in a sample of 171 young subjects undergoing transrectal
sonography for couple infertility and not complaining of
LUTS [43].We found an association between prostate volume
and insulin levels, which was retained after adjusting for
total testosterone, othermetabolic factors, and blood pressure
[43]. All these findings indicate that insulin is an independent
risk factor for BPH, most probably stimulating prostate
growth acting on IGF receptors [44]. Figure 1 shows the
relationship between increasing insulin levels (represented as
quartiles) and prostate total and transitional zone volume,
as detected by transrectal sonography, in the sample of
subjects consulting for couple infertility, collected as previ-
ously described [43]. The highest quartile of insulin levels is
associated with a clear increase in prostate size.
3.2. Obesity and BPH. In worldwide conducted studies,
obesity—and in particular visceral obesity—was found to
be often comorbid with BPH [45–49]. Although there were
also some negative reports [50, 51], a recent meta-analysis,
including a total of 19 studies, reported a positive association
between BMI and LUTS associated with BPH (odds ratio
(OR) = 1.28%) [52]. In population-based case-control studies,
a marginal positive association was observed between risk
of BPH and increased BMI. [52]. The impact of obesity
on prostate size is apparent even in early adulthood, as
demonstrated by a sonographic study conducted in 222
young men seeking medical care for couple infertility [53].
3.3. Dyslipidemia and BPH. The prostate synthesizes choles-
terol at a level similar to the liver and accumulates it in a
deposit within the gland in an age-dependent manner [54].
More than 70 years ago, Swyer [55] analyzed the cholesterol
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Table 1: Characteristics of the studies comparing International Prostatic Symptom score (IPSS) and prostate volume in patients with and
without metabolic syndrome (MetS) according to different criteria. NCEP-ATPIII: National Cholesterol Education Program-Third Adult
Treatment Panel; IDF: International Diabetes Federation; AHA/NHLBI: American Heart Association/National Heart, Lung, and Blood
Institute.
Overall population Men with MetS Men without MetS
Study MetS criteria Age (years) Number of pts IPSS totalscore
Prostate
volume (cc) Number of pts
IPSS total
score
Prostate
volume (cc)
Ozden et al.,
2007 [67] NCEP ATP III 60 38 22 37.4 40 20 32
Park et al.,
2008 [68] NCEP ATP III 74 ± 8.1 102 11.1 41.7 246 12.3 40.4
Yim et al.,
2011 [69] NCEP ATP III 41.4 ± 5.2 140 — 18.4 708 — 17.8
Jeong et al.,
2011 [70] NCEP ATP III 46.4 ± 8.4 354 6.8 20.6 1003 6.5 19.7
Byun et al.,
2011 [71] NCEP ATP III 55.6 ± 9.72 209 6.85 31.4 499 7.89 29.8
Yang et al.,
2012 [72] NCEP ATP III 53.8 ± 6.9 142 — 30.1 278 — 25.2
Gacci et al.,
2013 [4] AHA/NHLBI; IDF 68.2 ± 7.4 86 22.5 63 185 20.9 58
Park et al.,
2013 [73] NCEP ATP III 50–59 355 10 34 869 10 28
content in the prostate of BPH subjects and reported that
its concentration was twice that in a normal prostate. Later
on, Nandeesha et al. [56] reported that circulating total and
HDL cholesterol were associated, in a positive and negative
manner, respectively, with prostate enlargement in a series of
50 symptomatic BPH cases and 38 controls. However, other
studies did not confirm the association [57–59]. In the Ran-
cho Bernardo cohort study, Parsons et al. [60] found a 4-fold
increased risk of BPH among diabetic men with elevated low
density lipoprotein (LDL) cholesterol, but not in the overall
cohort. This observation suggests that dyslipidemia per se is
not sufficient enough to concur with BPH determinism, but
the presence of other metabolic derangements, like T2DM,
favors the process, because of an unfavorable total and LDL
cholesterol particle size and density [60].
3.4. Hypertension and BPH. An association between BPH,
hypertension, and T2DM was originally reported in a retro-
spective study 50 years ago [61]. Later on, hypertension was
associated with increased odds of surgery for BPH in the
Physician’s Health Study [62] and with a higher prevalence
of LUTS in other studies [63–65]. However, because both
hypertension and BPH prevalence increase as a function
of aging, the relationship between the two conditions was
underlooked.
3.5. Metabolic Syndrome and BPH. From all the previ-
ous considerations (see Sections 3.1–3.4) it can be derived
that each individual factor of MetS has been associated
in some study with BPH/LUTS prevalence or progression,
although several authors noted that their clustering, more
than their individual presence, underlies the link. In 1998,
Hammarsten et al. [66] elaborated this concept investigating
the relationship between prostate volume and individual
MetS components in 158 men with BPH, demonstrating that
T2DM, hypertension, obesity, high insulin, and low HDL-
cholesterol levels were all risk factors for the development
of BPH. Thereafter, only few additional studies, based on
the concept of the MetS construct, have investigated the
association between MetS and BPH/LUTS; results are sum-
marized in Table 1 [4, 67–73]. All the studies found an
association between the presence of MetS, even if defined
with different criteria, and prostate volume, whereas the
relationship between MetS and LUTS is more controversial
(see Table 1). However, changing definition of MetS has little
impact on its long-termmetabolic and CV consequences [74,
75]. In the study of Gacci et al. [4], reduced HDL-cholesterol
and increased triglyceride levels were noted to be the main
determinants of MetS-related prostate alterations.
A recently published epidemiological survey of the
Boston area (BACH) confirmed an association betweenMetS
and LUTS; however, when subjects were stratified by age, the
association was confirmed only in the youngest individuals
[76].
In the previously mentioned cohort of relatively young
male subjects examined for couple infertility we recently
reported a stepwise, component-dependent association
between increasing MetS severity and prostate enlargement
at color Doppler ultrasound (CDU) [43]. No association
between MetS-related prostate CDU abnormalities and
semen parameters was detected, even though, in this
cohort, MetS was associated with poor sperm morphology
[43, 77]. Increased central obesity and reduced HDL
cholesterol were the main correlates of prostate enlargement
in this young, asymptomatic population. This and previous
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evidence suggest that, beginning at a young age, MetS and
in particular high waist circumference and reduced HDL
cholesterol play an important role in prostate overgrowth.
Interestingly, no association between MetS severity and
prostate-related symptoms was observed, using either IPSS
or the National Institutes of Health Chronic Prostatitis
Symptom Index (NIH-CPSI) [43], which is a brief self-
reported questionnaire for screening prostatitis symptoms
[78].
4. BPH/LUTS and Inflammation
4.1. Epidemiological Evidence. In the last decade, cross-
sectional and longitudinal observation of several large
cohorts have finally confirmed that chronic inflammation is
a crucial component of BPH pathogenesis. An examination
of baseline prostate biopsies in a subgroup of 1,197 patients,
followed for more than 4 years in the Medical Therapies of
Prostate Symptoms (MTOPS) study to assess BPH-disease
progression, found that men in the placebo arm with inflam-
mation were significantly more likely to experience BPH
worsening and at higher risk of acute urinary retention
(AUR) or BPH-related surgery than those without [79]. This
was confirmed in the subgroup analysis of 8,224 men in
the Reduction by Dutasteride of Prostate Cancer Events
(REDUCE) trial indicating that histologic inflammation was
present in more than 78% men and that the severity of
LUTS and the intensity of inflammation were related [80].
Another study retrospectively reviewed all histopathological
examinations of 3,942 patients with BPH and showed that
43%of patients had histologic inflammation and 69%of them
had chronic inflammation. In addition, inflammation in the
prostate increased significantly with the increase in prostate
volume and age [81]. Finally, the data from the placebo
arm (1359 men) of the Prostate Cancer Prevention Trial
(PCPT) demonstrated that circulating levels of inflammatory
markers, including elevated CRP and interleukin-6 (IL-6),
were associated with risk of incident, symptomatic BPH [82].
4.2. Physiopathology. Within the prostate, several classes of
immunocompetent cells (lymphocytes, macrophages, and
granulocytes) are physiologically resident and termed human
prostate-associated lymphoid tissue (PALT). Activation of the
intraglandular immune system PALT is the usual response
to infectious agents. However, we believe that this initial
acute inflammation could be succeeded by chronic inflam-
mation that persisted if favored by hormonal and metabolic
derangements or by exposure to other environmental and
dietary factors [83]. Activated PALT recruits and stimulates
the proliferation of other immunocompetent cells leading to
an upregulation of several proinflammatory chemokines and
cytokines [84]. Prostatic stromal cells—acting as targets of
bacterial or viral toll-like receptor (TLR) agonists and, later
on, as antigen-presenting cells (APC)—play a crucial role in
the induction of inflammatory responses.They in fact activate
CD4+ lymphocytes and favor their differentiation to the
effector subsetsTh1 andTh17 [85]. In addition, TLR activation
leads to the production of proinflammatory cytokines (IL-6)
and chemokines (IL-8 and CXCL10) capable of recruiting
CXCR1- and CXCR2-positive leukocytes and CD15+ neu-
trophils and further promoting prostate cell hyperplasia,
through the direct action of IL-8 or the release of other
intraprostatic growth factors, like basic FGF [85–87]. Stromal
BPH cells are able to secrete IL-8, CXCL-10, and IL-6 not only
in response to specific proinflammatory stimuli (i.e., TNF𝛼 or
the TLR 4 agonist lipopolysaccharide), but also to metabolic
insults and, in particular, to oxidized LDL and insulin. This
suggests the hypothesis that lipids can induce and sustain an
inflammatory response in human prostatic cells [87, 88].
4.3. Clinical Evidence. In line with this preclinical evidence,
in a multicentre study on 271 consecutive men treated with
simple prostatectomy, we demonstrated that the presence of
MetS—and in particular of some of its components, such
as dyslipidemia—is associated with a more severe intrapro-
static inflammation [87, 88]. In particular, histopathologi-
cal examination of BPH specimens demonstrated that the
inflammatory score (IS), as well as the positivity for the pan
leukocyte marker CD45, significantly increased as a function
of MetS components [86–88]. Among MetS components,
reduced HDL cholesterol and elevated triglycerides were
significantly associated with elevated IS and CD45 positivity.
Fats could have, therefore, a detrimental effect on prostate
cells, boosting prostate inflammation, a key factor in the
development and progression of BPH/LUTS. In the previ-
ously mentioned cohort of young, infertile subjects [43], we
noted a significant, stepwise correlation between the number
of MetS components and seminal IL-8, which has been
proposed as a surrogate marker of prostate inflammation
[89–92]. In addition, in the same population, a higher
MetS severity was associated with sonographic features of
prostate inflammation, including texture nonhomogeneity,
major calcification size, and elevated arterial peak systolic
velocity. Abdominal adiposity and dyslipidemia were the
main determinants, among MetS factors, of sonographic
alterations and increased seminal IL-8 [43].
4.4. Experimental Models of MetS and Prostate Inflamma-
tion. We recently developed an animal model of MetS by
feeding New Zealand male rabbits a high fat diet (HFD)
for 12 weeks. MetS in rabbits was characterized by glucose
intolerance, dyslipidemia, hypertension, increased visceral
fat accumulation, and hypogonadotropic hypogonadismwith
a concomitant hyperestrogenism [93–95]. In MetS animals
we have described a specific prostate [96] and bladder
[93] phenotype, which includes features of inflammation,
tissue remodeling, and hypoxia. Interestingly, almost all these
alterations were positively associated with a low-testosterone
and high-estrogen milieu [93, 96, 97]. Accordingly, Figure 2
(upper panel) shows thatMetS severity, in rabbit fedHFDor a
regular diet (RD), is associated with a stepwise increase in AR
and ER𝛼, but not ER𝛽 (not shown), gene expression within
the prostate. In addition, in the same figure, it is shown that
also the nonclassical, G protein-coupled estrogen receptor,
GPER/GPR30, increases as a function of number of MetS
factors. This indicates a potentially increased sensitivity of
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Figure 2: Gene expression of sex steroid receptors (upper panel) and inflammatory markers (middle and lower panels) in prostate of rabbits
fed a regular diet (RD) or a high fat diet (HFD), according tometabolic syndrome (MetS severity). MetS severity was categorized as previously
described [138], according to the number of factors present (abscissa). Ordinate axis indicates level of mRNA expression in arbitrary unit, as
derived from quantitative RT-PCR analysis of the indicated prostate samples. Level of significance was derived from Kruskall-Wallis analysis
of the data.
the MetS prostate to changing sex steroids. We, in fact, found
that T administration to HFD rabbits reverted the majority
of MetS-induced prostate alterations [96]. This finding is in
line with the observation that, in human BPH stromal cells,
the selective AR agonist DHT was able to blunt TNF𝛼, LPS,
or CD4(+)T cell-induced secretion of inflammatory/growth
factors, including IL-6, IL-8, and bFGF, by blocking NF-
𝜅B nuclear translocation [86]. A protective effect of DHT
was also found on oxLDL- or insulin-induced IL-8 secretion
[87]. Interestingly, DHT was also able to prevent TNF𝛼-
induced LOX-1 (the receptor for oxLDL) mRNA expression.
This strongly indicates a potential beneficial effect of AR
signaling on diet-induced prostate inflammation. In contrast,
tamoxifen dosing to HFD rabbits further exacerbated MetS-
induced prostate alterations, most probably by stimulating
GPER/GPR30, as demonstrated by experiments with selec-
tive ligands for these receptors and by genetic ablation of their
expression [26].
We also recently reported that the prostate of HFD-
rabbits showed an increased expression of both mRNA and
protein for phosphodiesterase type 5 (PDE5), the enzyme that
catalyzed cGMP breakdown [97]. PDE5 expression within
the prostate was associated with the majority of HFD-
inducedmarkers of inflammation, fibrosis, andmyofibroblast
activation, and, in particular, with COX2 and TNF𝛼 among
inflammatory genes and with TGF𝛽, ROCK2, and 𝛼SMA
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Table 2: Characteristics of the studies included in the meta-analysis.
Overall population
Study Age (years) Duration (weeks) Drugs Dosage (mg) Placebo number of pts PDE5 number of pts
McVary et al., 2007 [113] 60 12 Sildenafil 50 (2 weeks); 100 155 168
McVary et al., 2007 [114]∗ 61.5 12 Tadalafil 5 (6 weeks); 20 126 125
Stief et al., 2008 [115] 55.9 8 Vardenafil 10 110 105
Roehrborn et al, 2008 [116]∗ 62.0 12 Tadalafil 2.5; 5; 10; 20 185 701
Porst et al., 2009 [117]∗ 61.9 12 Tadalafil 2.5; 5; 10; 20 105 386
Tamimi et al., 2010 [118]∗ 60.9 12 UK-369003 10; 25; 50, 100 37 246
Porst et al., 2011 [119] 64.8 12 Tadalafil 5 152 148
Egerdie et al., 2012 [120]∗ 62.5 12 Tadalafil 2.5; 5 200 406
Oelke et al., 2012 [121] 63.6 12 Tadalafil 5 172 171
Brock et al., 2013 [122] 63.3 12 Tadalafil 5 545 544
Dmochwski et al., 2013 [123] 58.6 12 Tadalafil 20 101 99
Yokoyama et al., 2013 [124]∗ 63.2 12 Tadalafil 2.5; 5 154 306
∗The effect derived from a ponderated mean at end point on International Prostate Symptom Score and maximum urinary flow rate were analyzed.
among those genes specifically involved in fibrosis and
myofibroblast activation. Interestingly, HFD-induced PDE5
overexpression was counteracted by T dosing. Consistent
with this effect, a negative correlation between prostate PDE5
mRNA expression and plasma testosterone/estradiol ratio
was identified. However, a direct role of hypogonadism in
HFD-induced PDE5 upregulationwas ruled out by the obser-
vation that hypogonadotropic hypogonadal rabbits (GnRH
analog-treated group), characterized by a reduced plasma
testosterone/estradiol ratio, showed prostatic PDE5 mRNA
expression similar to that of the RD group, which was not
modified by T treatment [97]. Hence, we can hypothesize that
HFD-related derangements, rather than hypogonadism per
se, may be related to the PDE5 overexpression in the prostate.
5. Possible Intervention in
MetS-Associated BPH/LUTS
Current therapy for BPH/LUTS is largely based on the
use of 𝛼
1
-adrenergic receptor blockers, which relax pro-
static smooth muscle, and 5-𝛼 reductase inhibitors, which
reduce prostatic volume. Accordingly, current EAU guide-
lines attributed level of evidence of 1b and 1a to 𝛼
1
-blockers
and 5-𝛼 reductase inhibitors, respectively, for the treatment of
men with moderate-to-severe LUTS [98]. Recently, the pos-
sible use of PDE5 inhibitors was also recognized as a valuable
treatment of the condition, with a level of evidence of 1b [98].
However, the same guidelines also suggest the usefulness of
lifestyle modifications, without better explanation except for
avoidance or moderation of caffeine or alcohol intake that
mayhave a diuretic and irritant effect, thereby increasing fluid
output and enhancing frequency, urgency, and nocturia [98].
5.1. Lifestyle Modification. Current evidence, suggesting a
close relationship among BPH/LUTS, MetS, hypogonadism,
and inflammation, indicates that the impact of lifestyle
modification should be more carefully analyzed. Prospective
data of the Health Professionals Follow-up Study (HPFS), on
more than 18,000 men without LUTS at baseline, recently
showed that men with higher total and abdominal adiposity
orwho gainedweight at follow-upweremore likely to develop
LUTS or experience progressive LUTS [99]. Previous meta-
analyses have clearly demonstrated that lifestyle modifica-
tions, such as weight loss and increased consumption of fruit
and vegetables, can reduce the incidence of obesity-related
morbidities including hypogonadism [100], type 2 diabetes
[101], coronary artery disease [102], and stroke [103]. Quite
unexpectedly, studies on efficacy of lifestyle modifications on
BPH/LUTS outcome are still lacking.
In 2002, Suzuki et al. [104] first reported that men with
high energy intakes and particularly with high consumption
of protein and polyunsaturated fatty acidwere at a greater risk
of developing BPH.Data from the placebo arm in the Prostate
Cancer Prevention Trial (PCPT), which enrolled 18,880 men
aged over 50 years, confirmed that high consumption of red
meat and a high fat diet increased the risk of BPH [105]. In
addition, the same authors reported that high consumption
of vegetables reduced risk of BPH [105]. Similarly, data from
HPFS study have demonstrated that consumption of fruits
and vegetables rich in 𝛽-carotene lutein or vitamin C was
inversely related to BPH [106]. As reported above, oxidative
damage and inflammation are thought to be associated with
development of BPH. High consumption of unsaturated
fatty acids might contribute to lipid peroxidation of the cell
membrane exacerbating the inflammation and impairing 5𝛼-
reductase activity [107]. Conversely, high intake of fruits and
vegetables was found to be associated with less oxidative
stress, as measured by malondialdehyde concentration [108].
The effect of diet on BPH/LUTS is also supported by the
lower incidence of prostate related problems in some Asian
countries using a predominantly plat-based diet, as compared
with Western countries, using a provokingly animal-based
diet [109].
Physical activities were also shown to reduce the pos-
sibility of prostate enlargement, LUTS, and LUTS-related
surgery [110]. In particular, increasing walking by 3 h/week
decreases the risk of BPHby 10% [110]. In ameta-analysis that
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Figure 3: Weighted differences (with 95% confidence interval (CI)) of International Prostate Symptom Score (IPSS; (a)) and maximum
flow rate (𝑄max; (b)), for the studies on phosphodiesterase type 5 inhibitors (PDE5-Is) versus placebo. § no erectile dysfunction; §§ erectile
dysfunction.
enrolled 43,083male patients, intensity of exercise was related
to reduction of risk of prostate enlargement. Compared to the
sedentary group, the risk for BPH or LUTS was significantly
reduced with OR = 0.70, 0.74, and 0.74 for men engaging in
light, moderate, and heavy physical activity, respectively [111].
In conclusion, type of diet and level of physical activity
are emerging as other important factors affecting prostate
health in the aging male, most probably reducing risk factors
such as MetS, hypogonadism, and inflammation. However,
whether physical exercise, weight loss, and modifications of
dietary habit can really alter the natural history of BPH/LUTS
remains to be determined. Further research is advisable to
better clarify these points.
5.2. PDE5 Inhibitors and BPH/LUTS. Emerging evidence
suggests that PDE5i might reduce moderate-to-severe (stor-
age and voiding) LUTS in men with or without ED [98].
Accordingly, tadalafil (5mg once daily) has been approved
by the US Food and Drug Administration (FDA) and by
the European Medical Agency (EMA) and licensed for
the treatment of male LUTS in Europe. By meta-analyzing
the available evidence we previously reported that PDE5i
alone, as compared with placebo, is able to improve LUTS
symptoms, as detected by the decrease of IPSS score [112]. In
addition, the association of PDE5i and𝛼1-adrenergic blockers
improved both IPSS score and maximum urinary flow rate
(𝑄max) at the end point, as compared with 𝛼 blockers alone
[112]. Since our last analysis, other five double-blind, placebo-
controlled, randomized clinical trials (RCT) comparing the
effect of PDE5i versus placebo on BPH/LUTS, have been
published (see Table 2). Hence, so far, 12 RCTs [113–124] have
specifically evaluated the effect of PDE5i alone in patients
with BPH/LUTS. Overall, the studies enrolled 5158 patients,
with a mean follow-up of 11.6 weeks (Table 2). Similar to
previous analysis [112], we now report that PDE5i treatment
was associated with a significant improvement of LUTS, as
detected by the reduction of total IPSS score (Figure 3(a)).
In addition, present meta-analysis also originally shows
that PDE5i users report a small, but significant, improve-
ment in 𝑄max (Figure 3(b)). Hence, the current analysis, in
International Journal of Endocrinology 9
a larger cohort of subjects, further indicates a role of PDE5i in
improving LUTS in patients with BPH. In addition, it shows
for the first time a possible role of PDE5i in improving urinary
outflow in the same category of subjects.
Despite the aforementioned clinical evidence, the mech-
anism of action (MOA) of this class of medication in
BPH/LUTS is still amatter of debate. Several dedicated recent
reviews are available on this topic [112, 125–127]. Preclinical
studies demonstrated that prostate, bladder, and urethra, as
well as their relative blood vessels, all represent potential
targets of PDE5i [128, 129]. Experimental evidence suggested
that chronic blockade of PDE5 could impact several pathways
involved in LUTS generation [88, 112, 125–127], including a
reduced nitric oxide (NO)/cyclic guanosine monophosphate
(cGMP) and an increased RhoA/Rho-kinase signalling [130–
132]. In addition, PDE5i can also reduce chronic pelvic
hypoxia and its related functional and morphologic changes
in the bladder and prostate, by increasing blood perfusion
[129, 133]. A possible direct effect for PDE5i in modulating
autonomic nervous system overactivity and bladder/prostate
afferent nerve activity was also suggested [134]. However, in
the last few years, some experimental and clinical data have
offered a newMOA for PDE5i in BPH/LUTS, reducingMetS-
associated prostate inflammation. In the previously described
rabbit model of MetS-associated prostate alterations we
found that tadalafil dosing was able to reduce inflamma-
tion and leukocyte infiltration (CD 45 scoring), along with
fibrosis/myofibroblast activation [97]. In a retrospective pilot
study on a BPH population (𝑛 = 60), previously enrolled in
a double-blind, placebo-controlled, clinical study on the effi-
cacy of daily vardenafil (10mg) added to tamsulosin (0.4mg)
[135], we evaluated prostatic CD 45 score in those undergoing
simple prostatectomy for persistent/recurrent severe urinary
symptoms. Patient cohort was categorized according to the
presence of MetS. In those without MetS, CD45 positivity
was low and unaffected by vardenafil dosing. In those with
MetS, increased CD45 positivity was significantly blunted
by chronic vardenafil treatment [88]. It is interesting to
note that even in this small cohort the MetS factor most
closely associated with CD45 positivity was dyslipidemia.
Interestingly, in isolated human BPH stromal cells both
tadalafil and vardenafil decreased TNF𝛼-induced expression
of genes related to inflammation (COX-2, IL-8, Il-6, IP-10,
and MCP-1) and tissue remodelling (𝛼SMA, bFGF). Similar
results were obtained when TNF𝛼-induced secretion of IL-8
and CXCR-10 was considered. Both vardenafil and tadalafil
were able to blunt IL-8 secretion induced also by metabolic
stimuli, such as oxLDL, AGE, and IGF-1. The effect was
apparently due to the ability of these PDE5i to stimulate
PKG activity because it was mimicked by a nonhydrolysable
cGMP analog and blocked by a PKG antagonist. Finally, both
PDE5i significantly reduced the ability of TNF𝛼 to increase
the expression of oxLDL receptor, LOX-1 [88].
6. Conclusions
People are living longer and, in some parts of the world,
healthier lives. In 2006, almost 500million people worldwide
Healthy
prostate
BPE
LUTS
Overt or subclinical
prostatitis
Dyslipidaemia
MetS
Low T/
high 17 𝛽E2
Bladder
dysfunction
Aging
Figure 4: Graphical representation of a proposed multifactorial
pathogenesis of benign prostatic hyperplasia/low urinary tract
symptoms (BPH/LUTS). Symptomatic or asymptomatic prostate
inflammation (very common in young individuals), in the presence
of permissive factors such as metabolic syndrome (MetS), and
in particular dyslipidemia, or an altered sex steroid milieu, can
progress through prostate enlargement (BPE). The latter can or
cannot be associated with LUTS, in particular in the presence of
bladder dysfunction. Recent data indicates that MetS itself can also
favour bladder alteration.
were 65 and older. By 2030, that total is projected to increase
to 1 billion—1 in every 8 of the earth’s inhabitants. Signifi-
cantly, themost rapid increases in the 65 and older population
are occurring in developing countries, which will see a jump
of 140 percent by 2030 [136]. Hence, we must proactively
face the health issues of the elderly. BPH/LUTS represent
significant bother among aging men; they were historically
considered as a “normal” consequence of the aging process
and, as such, their negative effects on men’s well-being only
dealt with throughmedical or surgical intervention.This view
has been challenged in the last decade and now BPH/LUTS
are seen more as preventable than inexorable ailments of
the elderly [137]. Evidence presented in this review indicates
that several modifiable metabolic factors play a role in the
determinism or progression of LUTS/BPH. MetS and its
components, hypogonadism, and prostate inflammation are,
in fact, emerging asmedical conditions commonly associated
with BPH/LUTS. Figure 4 summarizes our view. In our
view, BPH/LUTS may be viewed as a complex disorder that
also involves a metabolic component that may begin early
in the life of the male, and, although asymptomatic, it is
likely detectable even in the early stages of the disease. The
mechanisms underpinning the relationship between MetS
and prostate inflammation are likely to be similar in young
and old men but chronic exposure to elevated inflammation,
along with low T/high 17𝛽E2, may contribute to BPH in
the long term. Preventing the development of the disease
even from the asymptomatic phase should be the basis for
designing a resilient program of elderly healthcare. Analysis
of the European Prospective Investigation into Cancer and
Nutrition (EPIC)-Norfolk cohort has clearly demonstrated
10 International Journal of Endocrinology
that the adverse CV effects of having MetS on coronary
heart disease could be substantially reduced or nullified by
increasing physical activity. Several epidemiological studies
support this view also for BPH/LUTS; intervention studies
are urgently needed.
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